3 Catalysts Bristol-Myers Squibb Investors Need to Watch

Shares of pharmaceutical giant Bristol-Myers Squibb  (NYSE: BMY  ) have soared more than 40% since the start of 2013, and investor confidence in this high-flying stock is still high. However, in the world of health care investing, catalysts can either push shares up further or cool the market's optimism.

In the following video, a segment from the The Motley Fool's health care show Market Checkup, analysts Max Macaluso and David Williamson discuss three key catalysts that Bristol-Myers investors must watch. Among them are results from its oncology pipeline, the Food and Drug Administration decision on its type 2 diabetes drug Forxiga -- which it shares with AstraZeneca (NYSE: AZN  ) and could compete with Johnson & Johnson's (NYSE: JNJ  ) Invokana in the U.S. market -- and its virology program, which has lost ground to biotech Gilead Sciences  (NASDAQ: GILD  ) .

One of the best parts of owning big pharma stocks like Bristol is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool’s favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2651630, ~/Articles/ArticleHandler.aspx, 4/20/2014 12:25:27 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement